Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum Carbonate (Fosrenol) for reducing urinary oxalate in secondary hyperoxaluria with nephrolithiasis
2014-000308-82Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanthanum carbonate in Lithiasis, secondary hyperoxaluria and nephrolithiasis, sponsored by UZ Brussel. Primary endpoint: Mean reduction in urinary oxalate excretion at 750 mg daily. Started Jan 2017; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
Lithiasissecondary hyperoxalurianephrolithiasis
Beyond the preview
Go deeper on 2014-000308-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000308-82.